

AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

What is claimed:

1. (Original) A method of treating interstitial cystitis, comprising:
administering to an affected subject a pharmaceutically effective amount of a
composition comprising an RDP58 oligopeptide.
2. (Amended) The method of Claim 1, wherein the RDP58 oligopeptide consists of the
amino acid sequence: ~~Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr-~~ set forth as SEQ ID
NO:28.
3. (Original) The method of Claim 1, wherein at least one of the terminal amino acids is a
modified amino acid.
4. (Original) The method of Claim 3, wherein the modified amino acid is an amidated
amino acid or salts thereof.
5. (Original) The method of Claim 1, wherein one or more of the amino acids are D
isomers.
6. (Original) The method of Claim 5, wherein all the amino acids are the D-isomer.
7. (Original) The method of Claim 1, wherein administering is by intravesicle instillation.
8. (Original) The method of Claim 1, wherein the interstitial cystitis is acute interstitial
cystitis.
9. (Original) The method of Claim 1, wherein the interstitial cystitis is chronic interstitial
cystitis.
10. (Original) A method of treating interstitial cystitis, comprising contacting disease
affected tissue or cells with a pharmaceutically effective amount of a composition
comprising an RDP58 oligopeptide to ameliorate a manifestation of interstitial cystitis.

Serial No.: 10/535,167
Filing Date: November 17, 2003

11. (Original) The method of Claim 10, wherein the manifestation is histamine release and the cells are mast cells.
12. (Original) The method of Claim 10, wherein the manifestation is Substance P expression.
13. (Original) The method of Claim 10, wherein the manifestation is NGF expression.
14. (Original) The method of Claim 10, wherein the manifestation is TNF- α expression.
15. (Original) The method of Claim 10, wherein the manifestation is degradation of urine/blood barrier.
16. (Amended) The method of any one of Claims 10-15, wherein the RDP58 oligopeptide consists of the amino acid sequence ~~Arg-nL-nL-nL-Arg-nL-nL-nL-Gly-Tyr~~. set forth as SEQ. ID NO:28.
17. (Original) The method of Claim 16, wherein one or more of the amino acids of the oligopeptide are the D-isomer.
18. (Original) The method of Claim 17, wherein all the amino acids of the oligopeptide are the D-isomer.
19. (Original) The method of Claim 16, wherein at least one terminal amino acid residue is a modified amino acid.
20. (Original) The method of Claim 19, wherein the modified amino acid is an amidated amino acid or salts thereof.